A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients with CD123-Expressing Hematologic Malignancies
The goal of this clinical research study is to learn about the safety of giving XmAb14045 to patients that have blood or bone marrow cancer. Researchers also want to learn the highest tolerable dose of XmAb14045 that can be given. This is the first study using XmAb14045 in humans.
Treatment Location: N/A
IRB Review and Approval Date: 08/16/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: